+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

From
Autoimmune Treatment Global Market Report 2024 - Product Thumbnail Image

Autoimmune Treatment Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
Antibody Drugs: Technologies and Global Markets 2021-2026 - Product Thumbnail Image

Antibody Drugs: Technologies and Global Markets 2021-2026

  • Report
  • October 2021
  • 133 Pages
  • Global
From
From
Crohn's Disease (CD) Treatment Global Market Report 2024 - Product Thumbnail Image

Crohn's Disease (CD) Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
From
From
From
Primary Immune Deficiency (PID) - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Immune Deficiency (PID) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Myasthenia Gravis - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Myasthenia Gravis - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • July 2021
  • 148 Pages
  • Global
From
From
From
Loading Indicator